局部晚期结肠癌新辅助化疗与直接手术后的生存与安全性:Meta分析
该系统综述与Meta分析检索MEDLINE和Scopus,纳入截至2023年4月1日发表的随机对照试验、倾向性评分匹配研究和对照前瞻性研究,共7项研究2120例局部晚期(T3-4 Nx-2 M0)结肠癌患者。与直接手术相比,新辅助化疗与复发风险降低(HR 0.73,95%CI 0.59-0.90;P=0.003)和死亡风险降低(HR 0.67,95%CI 0.54-0.83;P<0.001)相关,5年总生存率(79.9% vs 72.6%;P<0.001)和无病生存率(73.1% vs 64.5%;P=0.028)更高,围术期死亡率、总体并发症及吻合口漏/腹腔脓肿无显著差异,不完全切除风险更低(OR 0.70,95%CI 0.49-0.99)。
要点
- 新辅助化疗较直接手术降低复发风险(HR 0.73,95%CI 0.59-0.90;P=0.003)和死亡风险(HR 0.67,95%CI 0.54-0.83;P<0.001)。
- 新辅助化疗组5年总生存率79.9% vs 直接手术组72.6%(P<0.001),无病生存率73.1% vs 64.5%(P=0.028)。
- 围术期死亡率、总体并发症及吻合口漏/腹腔脓肿无显著差异,不完全切除风险更低(OR 0.70,95%CI 0.49-0.99)。
核心结论
- 在局部晚期结肠癌患者中,与直接手术相比,新辅助化疗与复发风险降低和死亡风险降低相关,并改善总生存率和无病生存率。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE和Scopus数据库,纳入截至2023年4月1日发表的随机对照试验、倾向性评分匹配研究和对照前瞻性研究,共7项研究2120例患者,采用DerSimonian and Laird模型分析。
主要发现
- 新辅助化疗与直接手术相比,复发风险降低(HR 0.73,95%CI 0.59-0.90;P=0.003),死亡风险降低(HR 0.67,95%CI 0.54-0.83;P<0.001)。
- 新辅助化疗组5年总生存率为79.9%,直接手术组为72.6%(P<0.001);新辅助化疗组5年无病生存率为73.1%,直接手术组为64.5%(P=0.028)。
- 围术期死亡率(OR 0.97,95%CI 0.28-3.33)、总体并发症(OR 0.95,95%CI 0.77-1.16)及吻合口漏/腹腔脓肿(OR 0.88,95%CI 0.60-1.29)在两组间无显著差异。
- 新辅助化疗与不完全切除风险降低相关(OR 0.70,95%CI 0.49-0.99)。
关键数值与推荐
- 新辅助化疗与直接手术相比:复发HR 0.73(95%CI 0.59-0.90;P=0.003),死亡HR 0.67(95%CI 0.54-0.83;P<0.001)。
- 5年总生存率:新辅助化疗组79.9% vs 直接手术组72.6%(P<0.001);5年无病生存率:新辅助化疗组73.1% vs 直接手术组64.5%(P=0.028)。
- 围术期死亡率OR 0.97(95%CI 0.28-3.33),总体并发症OR 0.95(95%CI 0.77-1.16),吻合口漏/腹腔脓肿OR 0.88(95%CI 0.60-1.29),均无显著差异。
- 不完全切除OR 0.70(95%CI 0.49-0.99),新辅助化疗组风险更低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy is increasingly used to treat locally advanced (T3-4 Nx-2 M0) colon cancer due to its potential advantages over the standard approach of upfront surgery. The primary objective of this systematic review and meta-analysis was to analyse data from comparative studies to assess the impact of neoadjuvant chemotherapy on oncological outcomes. METHODS: A systematic review was conducted by searching the MEDLINE and Scopus databases. The search encompassed RCTs, propensity score-matched studies, and controlled prospective studies published up to 1 April 2023. As a primary objective, overall survival and disease-free survival were compared. As a secondary objective, perioperative morbidity, mortality, and complete resection were compared using the DerSimonian and Laird models. RESULTS: A total of seven studies comprising a total of 2120 patients were included. Neoadjuvant chemotherapy was associated with a reduction in the hazard of recurrence (HR 0.73, 95% c.i. 0.59 to 0.90; P = 0.003) and death (HR 0.67, 95% c.i. 0.54 to 0.83; P < 0.001) compared with upfront surgery. Additionally, neoadjuvant chemotherapy was significantly associated with higher 5-year overall survival (79.9% versus 72.6%; P < 0.001) and disease-free survival (73.1% versus 64.5%; P = 0.028) rates. No significant differences were observed in perioperative mortality (OR 0.97, 95% c.i. 0.28 to 3.33), overall complications (OR 0.95, 95% c.i. 0.77 to 1.16), or anastomotic leakage/intra-abdominal abscess (OR 0.88, 95% c.i. 0.60 to 1.29). However, neoadjuvant chemotherapy was associated with a lower risk of incomplete resection (OR 0.70, 95% c.i. 0.49 to 0.99). CONCLUSION: Neoadjuvant chemotherapy is associated with a reduced hazard of recurrence and death, as well as improved overall survival and disease-free survival rates, compared with upfront surgery in patients with locally advanced colon cancer. Colon cancer is a common medical condition, the established treatment for which involves surgical resection followed by chemotherapy. However, a contemporary shift has led to the investigation of an alternative treatment sequence known as neoadjuvant chemotherapy, wherein chemotherapy precedes the surgery. This study critically assesses the efficacy of neoadjuvant chemotherapy compared with the standard treatment approach of surgery followed by chemotherapy. A systematic review of medical databases was undertaken to identify pertinent research publications on this subject matter. In total, seven studies encompassing data from 2120 patients were included in the analysis. Employing a meta-analysis methodology to synthesize the collective data from these studies, it was revealed that neoadjuvant chemotherapy was linked to higher rates of 5-year overall survival and disease-free survival, alongside a diminished hazard of both recurrence and death. Furthermore, no discernible differences in surgical complications or perioperative mortality were evident across the compared approaches.
引用
- Aliseda D, Arredondo J, Sánchez-Justicia C, et al. Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis. Br J Surg. 2024. PMID: 38381934. doi:10.1093/bjs/znae021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。